(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) for a year as post-surgery ...

Swiss pharma company Roche ... FDA Priority Review status for a Perjeta (pertuzumab) regimen to be used before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

ZURICH -- Roche Holding AG (ROG.VX ... closer to the approval of a new personalised medicine for people with this aggressive form of breast cancer," said Hal Barron, Roche's Chief Medical Officer ...

A study involving an experimental cancer drug being developed by Roche Holding (RHHBY, ROG.VX) showed it delayed disease progression in women with a specific type of breast cancer compared to ...

The US Food and Drug Administration has granted a Priority Review ... Roche evaluation its Imlygic (talimogene laherparepvec) in combination with atezolizumab in triple-negative breast cancer ...